Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes

被引：0
|
作者：
Julián Panés
Chinyu Su
Andrew G Bushmakin
Joseph C Cappelleri
Carla Mamolo
Paul Healey
机构：
[1] Hospital Clínic de Barcelona. IDIBAPS,
[2] CIBERehd,undefined
[3] Pfizer Inc,undefined
[4] Pfizer Inc,undefined
来源：
BMC Gastroenterology | / 15卷
关键词：
Ulcerative colitis; Patient reported outcomes; Quality of life; Tofacitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
    Panes, Julian
    Su, Chinyu
    Bushmakin, Andrew G.
    Cappelleri, Joseph C.
    Mamolo, Carla
    Healey, Paul
    [J]. BMC GASTROENTEROLOGY, 2015, 15
  • [2] Tofacitinib in active ulcerative colitis: Analysis of efficacy based on patient-reported outcomes
    Panes, J.
    Su, C.
    Bushmakin, A. G.
    Cappelleri, J. C.
    Mamolo, C.
    Healey, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S51 - S51
  • [3] Improvement in patient-reported outcomes in 2 Phase 3 studies of tofacitinib in patients with moderately to severely active ulcerative colitis
    Panes, J.
    Su, C.
    Marren, A.
    Yu, D.
    Woodworth, D.
    Zhang, H.
    Healey, P.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S283 - S284
  • [4] Improvement in Patient-Reported Outcomes in Two Phase 3 Induction Studies of Tofacitinib in Patients With Moderately to Severely Active Ulcerative Colitis
    Panes, Julian
    Su, Chinyu
    Marren, Amy
    Yu, Dahong
    Woodworth, Deborah A.
    Zhang, Haiying
    Healey, Paul J.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S1003 - S1003
  • [5] Patient-Reported Outcome Improvement with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program
    Hudesman, David
    Torres, Joana
    Salese, Leonardo
    Woolcott, John C.
    Mundayat, Rajiv
    Su, Chinyu
    Mosli, Mahmoud H.
    Allegretti, Jessica R.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S403 - S404
  • [6] PATIENT-REPORTED OUTCOMES ON THE IMPACT OF ORAL STEROID TREATMENT IN ULCERATIVE COLITIS
    Jayasooriya, Nishani
    Blackwell, Jonathan
    Pollok, Richard
    [J]. GUT, 2021, 70 : A78 - A79
  • [7] Clinical Long-Term Outcomes of Patient-Reported Outcomes in the Prospective Real-World Tofacitinib Response in Ulcerative Colitis Registry
    Herfarth, Hans H.
    Afzali, Anita
    Fischer, Monika
    Hudesman, David
    Abdalla, Maisa
    Mccabe, Robert
    Cohen, Benjamin L.
    Ungaro, Ryan C.
    Harlan, Will
    Hanson, John
    Konijeti, Gauree G.
    Polyak, Steven
    Ritter, Timothy
    Salzberg, Bruce
    Seminerio, Jennifer
    English, Emily
    Zhang, Xian
    Long, Millie D.
    [J]. CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (03)
  • [8] Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
    Sandborn, William J.
    Ghosh, Subrata
    Panes, Julian
    Schreiber, Stefan
    D'Haens, Geert
    Tanida, Satoshi
    Siffledeen, Jesse
    Enejosa, Jefferey
    Zhou, Wen
    Othman, Ahmed A.
    Huang, Bidan
    Higgins, Peter D. R.
    [J]. GASTROENTEROLOGY, 2020, 158 (08) : 2139 - +
  • [9] PREDICTIVE VALUE OF PATIENT-REPORTED OUTCOMES TO MUCOSAL HEALING IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Colombel, J. F.
    Han, C.
    Reinisch, W.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Gibson, P.
    Collins, J.
    Rutgeerts, P.
    Sandborn, W.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A40 - A40
  • [10] Comparing Patient-Reported Outcomes Among Anti-TNF Experienced Patients With Ulcerative Colitis Initiating Vedolizumab Versus Tofacitinib
    Kappelman, Michael D.
    Long, Millie D.
    Zhang, Xian
    Lin, Feng-Chang
    Weisbein, Laura
    Chen, Wenli
    Burris, Jessica
    Dorand, Jennifer E.
    Parlett, Lauren E.
    Fehlmann, Tara
    Brensinger, Colleen M.
    Haynes, Kevin
    Nair, Vinit
    Kaul, Alan F.
    Dobes, Angela
    Lewis, James D.
    [J]. CROHNS & COLITIS 360, 2023, 5 (03)
12345